66.23
+0.24(+0.36%)
Currency In USD
| Previous Close | 65.99 |
| Open | 66.31 |
| Day High | 68.77 |
| Day Low | 65.24 |
| 52-Week High | 68.8 |
| 52-Week Low | 19.45 |
| Volume | 741,618 |
| Average Volume | 757,716 |
| Market Cap | 4.77B |
| PE | -18.4 |
| EPS | -3.6 |
| Moving Average 50 Days | 60.68 |
| Moving Average 200 Days | 43.67 |
| Change | 0.24 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $1,991.28 as of December 05, 2025 at a share price of $66.23. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 3 years ago, it would be worth $2,275.16 as of December 05, 2025 at a share price of $66.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
GlobeNewswire Inc.
Nov 25, 2025 12:00 PM GMT
Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phase 1b AD trial with data to be reported in December
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
GlobeNewswire Inc.
Oct 28, 2025 11:00 AM GMT
WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third q
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
GlobeNewswire Inc.
Oct 27, 2025 11:00 AM GMT
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies KT-579 Phase 1